CAMBRIDGE, England--(BUSINESS WIRE)--CN Bio, a leading provider of single- and multi-organ microphysiological systems, today announced it has raised a $21 million investment in the first close of its Series B fundraising round. The funding has been secured from several new investors; including $10 million from Bayland Capital, and $5.5 million from founding shareholder, CN Innovations Holdings Ltd.

英国剑桥--（商业新闻短讯）--单器官和多器官微生理系统的领先提供商CN Bio今天宣布，在B轮融资的第一轮结束时，它已经筹集了2100万美元的投资。资金已经从几个新投资者那里获得；其中包括来自Bayland Capital的1000万美元，以及来自创始股东CN Innovations Holdings Ltd.的550万美元。

The investment will be used to accelerate the Company’s expanding product portfolio and to scale the business to support commercial expansion across key global markets..

该投资将用于加速公司不断扩大的产品组合，并扩大业务规模，以支持跨关键全球市场的商业扩张。

The global OOC market’s CAGR is estimated at 30.94%1. This growth has been accelerated, in part, by the need for biopharmaceutical companies to improve the efficiency and success rate of innovative drug R&D and recent legislative changes, such as the US FDA Modernization Act 2.0. In response, CN Bio is delivering an ambitious expansion strategy to meet the increasing demand for its PhysioMimix® OOC technology and research services, and to provide deeper, clinically-relevant insights into early-stage preclinical drug discovery in a wider range of application areas, whilst reducing reliance on animal models.

全球OOC市场的复合年增长率估计为30.94%1。部分原因是生物制药公司需要提高创新药物研发的效率和成功率，以及最近的立法变化，例如美国FDA现代化法案2.0，加速了这种增长。作为回应，CN Bio正在实施一项雄心勃勃的扩张战略，以满足对其PhysioMimix®OOC技术和研究服务日益增长的需求，并为更广泛的应用领域的早期临床前药物发现提供更深入的临床相关见解，同时减少对动物模型的依赖。

Over the past year, this has included a series of high-profile appointments to expand the Company’s leadership team in the UK and US, new product launches, and strategic industry collaborations. Notably, in December 20232, it was confirmed that PhysioMimix OOC and its associated NASH ‘in-a-box’ kit provided critical human-relevant compound efficacy data for Inipharm’s INI-822, supporting regulatory approval to initiate clinical testing for metabolic liver disease – a pivotal inflection point in CN Bio’s development, and the broader industry..

在过去的一年中，这包括一系列备受瞩目的任命，以扩大公司在英国和美国的领导团队，新产品发布以及战略性行业合作。值得注意的是，20232年12月，PhysioMimix OOC及其相关的NASH“in-a-box”试剂盒为Inipharm的INI-822提供了关键的人类相关化合物功效数据，支持监管部门批准启动代谢性肝病的临床测试-CN Bio发展和更广泛行业的关键转折点。

With the latest fundraising, CN Bio is well-positioned to continue its global expansion to meet the evolving needs of customers worldwide in key markets including toxicology, drug pharmacology and metabolic diseases. With 80% of clinical failures attributed to efficacy and toxicity issues, often derived from the poor predictiveness of animal and 2D cell culture models3, the industry demand for OOC solutions in these areas is growing.

通过最新的筹资活动，CN Bio将继续其全球扩张，以满足全球关键市场（包括毒理学、药物药理学和代谢疾病）客户不断变化的需求。由于80%的临床失败归因于功效和毒性问题，通常是由于动物和2D细胞培养模型的预测性差3，因此这些领域对OOC解决方案的行业需求正在增长。

By expanding R&D in the space, CN Bio will enhance the depth and breadth of tools and applications available to optimize drug discovery and development workflows, enabling researchers to generate data with greater predictability, lower risks of late-stage failures, and accelerate time-to-market for a wide-range of novel therapeutics..

通过扩大该领域的研发，CN Bio将提高可用于优化药物发现和开发工作流程的工具和应用程序的深度和广度，使研究人员能够生成具有更高可预测性的数据，降低晚期失败的风险，并加快各种新型治疗剂的上市时间。

Dr Paul Brooks, CEO, CN Bio, said: “We are seeing pivotal growth across our industry, whereby drug developers are increasingly recognising the potential of OOC technology to augment, supplement and optimize their workflows.” He added: “We have strategically positioned ourselves accordingly to respond to the market needs and are proud to have received recognition from our major shareholder, CN Innovations, and new institutional investors such as Bayland Capital, to drive this vision forward.

CN Bio首席执行官保罗·布鲁克斯（PaulBrooks）博士表示：“我们看到整个行业都取得了关键性的增长，因此药物开发商越来越认识到OOC技术在增强、补充和优化其工作流程方面的潜力。”他补充道：“我们已经对自己进行了相应的战略定位，以应对市场需求，并为获得我们的主要股东CN Innovations和Bayland Capital等新机构投资者的认可而感到骄傲，以推动这一愿景的实现。

The investment is a testament to our team’s hard work and dedication to best supporting our customers to bring drugs to patients more quickly, more cost-effectively, and through less animal experimentation.”.

这项投资证明了我们团队的辛勤工作和奉献精神，以最好的方式支持我们的客户更快，更具成本效益，通过更少的动物实验将药物带给患者。”

Yuexing Su, Founding Partner, Bayland Capital, commented: “OOC technology is an exciting market with compelling opportunity for growth. CN Bio has taken key steps to build a team with extensive industry expertise and robust networks across the industry, with a longstanding track record of success. We look forward to the continued success for the Company as it further capitalizes on this unique growth opportunity and delivers on its future expansion plans to remain at the cutting-edge of the field.

Bayland Capital创始合伙人苏跃兴（Yuexing Su）评论道：“OOC技术是一个令人兴奋的市场，具有令人信服的增长机会。CN Bio已采取关键步骤，建立了一支拥有广泛行业专业知识和强大行业网络的团队，并取得了长期的成功。我们期待该公司继续取得成功，因为它将进一步利用这一独特的增长机会，并实现其未来的扩张计划，以保持在该领域的领先地位。

We will leverage our networks and shareholders’ base to further support and cement the leading position of CN Bio in OOC development.”.

我们将利用我们的网络和股东基础，进一步支持和巩固CN Bio在OOC发展中的领先地位。”

Charles Chong, Managing Director, CN Innovations, added: “We are encouraged by CN Bio’s ongoing success and, in particular, the team’s achievements over the past years, during which conditions have been difficult in the broader economy. In this time, key milestones have been met, not just for the Company, but also the wider industry – including CN Bio providing critical human-relevant compound efficacy data to support the FDA’s approval for Inipharm’s Phase 1 clinical trial for metabolic liver disease.

CN Innovations董事总经理Charles Chong补充道：“我们对CN Bio不断取得的成功感到鼓舞，特别是该团队在过去几年取得的成就，在此期间，更广泛的经济状况一直很困难。在这段时间里，关键的里程碑已经实现，不仅对公司，而且对整个行业都是如此，包括CN Bio提供了关键的人类相关化合物功效数据，以支持FDA批准Inipharm的代谢性肝病1期临床试验。

We are pleased to be supporting CN Bio again as it looks ahead and strengthens its future growth plans, of which, expanding its product portfolio in markets that hold huge impact for the industry, such as metabolic disease modelling and toxicology, will be key.”.

我们很高兴再次支持CN Bio，因为它展望未来并加强其未来的增长计划，其中，在对行业产生巨大影响的市场（如代谢疾病建模和毒理学）中扩大其产品组合将是关键。”